Argentum Capital Partners

Argentum Pharmaceuticals is a generic pharmaceutical company focused on developing and commercializing high-value, high-complexity generic versions of branded drug products. The company is well-known for its strategic use of the Inter Partes Review (IPR) process to challenge and invalidate weak or secondary patents that protect expensive branded medications, thereby accelerating the entry of lower-cost generic alternatives. Argentum's business model involves identifying blockbuster drugs with vulnerable patent estates and partnering with manufacturing organizations to bring generic versions to market. Their portfolio and litigation efforts have targeted major therapies in areas such as immunology, neurology, and ophthalmology.